Qsymia

Qsymia combines two long-established drugs at low doses in one extended-release capsule taken once a day in the morning: phentermine, a stimulant appetite suppressant, and topiramate, an antiseizure medicine that happens to reduce appetite. Evening dosing is discouraged because of insomnia.

The dose schedule is a ladder with built-in decision points. Start at 3.75 mg/23 mg for 14 days, then move to 7.5 mg/46 mg. After 12 weeks at that dose, weight loss is evaluated: if an adult has not lost at least 3% of baseline body weight, the dose steps up to 11.25 mg/69 mg for 14 days and then to 15 mg/92 mg. After 12 weeks at the top dose, another check — if the patient has not lost at least 5% of baseline body weight, the label directs discontinuation. And the 15 mg/92 mg dose must be tapered, taken every other day for at least a week, because stopping it abruptly can trigger a seizure.

Pregnancy is the dominant safety issue. Topiramate exposure in the first trimester raises the risk of major congenital malformations including cleft lip and cleft palate, and of babies being small for gestational age. Because of that, Qsymia is distributed only through a restricted program — a Risk Evaluation and Mitigation Strategy — under which only certified pharmacies may dispense it. The label also recommends a negative pregnancy test before starting and monthly during therapy, plus effective contraception throughout.

Other label warnings include suicidal behavior and ideation (an antiepileptic class effect), acute myopia and secondary angle-closure glaucoma, and dose caps in moderate or severe kidney impairment and moderate liver impairment.

The common confusion is treating Qsymia as a gentler alternative to a GLP-1 because it is a pill. It is a different risk profile, not a smaller one. Worth asking your clinician: whether pregnancy is possible for you now or in the next year, whether you can get to a REMS-certified pharmacy, and what happens at each 12-week checkpoint. Our Qsymia side-effect review and topiramate weight-loss page go further.